Rome Therapeutics, a Cambridge, Mass.-based biotechnology company leveraging repeatome for drug development, launched with $50m in Series A funding.
Backers included GV, Arch Venture Partners and Partners Innovation Fund.
Led by CEO, President and Co-founder Rosana Kapeller, M.D., Ph.D., who incubated the company during her tenure as an entrepreneur-in-residence at GV, where she is currently a Fellow, Rome was founded to discover and develop novel therapies for cancer and autoimmune diseases by leveraging new insights from the vast uncharted territory of the repeatome – the roughly 60% of the human genome consisting of repetitive sequences of nucleic acids, known as repeats. Drawing on deep expertise in oncology, virology, immunology and machine learning, the team has identified several promising drug targets and launched multiple discovery programs.
Rome’s Board of Directors includes:
- Kristina Burow, Managing Director, ARCH Venture Partners
- Rosana Kapeller, M.D., Ph.D., Co-founder, CEO and President, ROME Therapeutics
- Jeb Keiper, CEO, Nimbus Therapeutics
- Julius Knowles, Partner, Partners Innovation Fund
- Jay Parrish, Ph.D., Chief Business Officer and Co-founder, Vir Biotechnology
- Krishna Yeshwant, M.D., General Partner, GV